DOI: https://dx.doi.org/10.18565/pharmateca.2022.4.76-80
И.А. Курникова, Ш.Г. Гулова, С.А. Бутурлина, И. Мохаммед
Российский университет дружбы народов, Москва, Россия
1. Arroyo-Johnson C., Mincey K.D. Obesity Epidemiology Worldwide. Gastroenterol Clin North Am. 2016;45(4):571-79. Doi: 10.1016/j. gtc.2016.07.012. 2. Bastard J., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12. 3. Клиническая рекомендация по ожирению 2020. URL: https://rae-org.ru/system/files/ documents/pdf/ozhirenie_vzroslye.pdf 4. Farooq M.A., Parkinson K.N., Adamson A.J., et al. Timing of the decline in physical activity in childhood and adolescence: Gateshead Millennium Cohort Study. Br J Sports Med. 2018;52:1002-6. Doi:10.1136/bjsports-2016-096933. 5. Lenz M., Richter T., Muhlhauser I. The morbidity and mortality associated with overweight and obesity in adulthood: a systematic review. Dtsch Arztebl Int. 2009;106:641-48. Doi: 10.3238/ arztebl.2009.0641. 6. Heymsfield S.B., Wadden T.A. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017;376(3):254-66. Doi:10.1056/NEJMra1514009. 7. Yeo G., Heisler L. Unraveling the brain regulation appetite: lessons from genetics. Nat Neurosci. 2012;15(10):1343-49. doi: 10.1038/nn.3211. 8. Zhi C., Huang J., Wang J., et al. Connection between gut microbiome and the development of obesity. Eur J Clin Microbiol Infect Dis. 2019;Jul 31. Doi: 10.1007/s10096-019-03623-x. 9. Fromentin C., Tome D., Nau F, et al. Dietary proteins contribute little to glucose production, even under optimal gluconeogenic conditions in healthy humans. Diabetes. 2013;62(5):1435- 42. Doi: 10.2337/db12-1208. 10. Veldhuis J.D., Sharma A., Roelfsema F., et al. Age-dependent and gender-dependent regulation of hypothalamic-adrenocorticotropic- adrenal axis Endocrinol Metab Clin North Am. 2013;42(2):201-25. Doi: 10.1016/j. ecl.2013.02.002. 11. Бобров А.Е., Гегель Н.А., Гурова О.Ю. Особенности поведения больных с избыточной массой тела и ожирением. Альманах клинической медицины. 2014;32:3-7. 12. Зайцев В.П., Зайцев В.П. Психологическая реабилитация больных. Медицинская реа-билитация. Под ред. В.М. Боголюбова. М.: БИНОМ, 2010. Т. 1. С. 325-47. 13. Дадаева В.А., Еганян Р.А., Королев А.И. и др. Типы нарушений пищевого поведения. Профилактическая медицина. 2021;24(4): 113-19. 14. Geliebter A., Christopher N., Ochner C.N., et al. Obesity-related hormones and metabolic risk factors: a randomized trial of diet plus either strength or aerobic training versus diet alone in overweight participants. J Diabetes Obes. 2015;1:1-7. 15. Stephens S.K., Cobiac L.J., Lennert Veerman. J. Improving diet and physical activity to reduce population prevalence of overweight and obesity: An overview of current evidence. Preventive Medicine. 2014;62:167-78. Doi: 10.1016/j. ypmed.2014.02.008. 16. Heymsfield S.B., Wadden T.A. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017;376(3):254-66. Doi:10.1056/NEJMra1514009. 17. Guh D., Zhang W., Bansback N., et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and metaanalysis. BMC Public Health. 2009;9:88. Doi: 10.1186/1471-2458-9-88. 18. Jensen M.D., Ryan D.H., Apovian C.M., et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: a report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(suppl2):S102-S138. Doi: 10.1161/01.cir.0000437739.71477.ee 19. Garvey W.T., Mechanick J.I., Brett E.M., et al.; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl 3):1-203. Doi: 10.4158/EP161365.GL. 20. Wirth A. Reduction of body weight and comorbidities by rollstart: The XXL primary Health Care Trial. Diabetes Obes. Metabol. 2005;7:2122. Doi: 10.1111/j.1463-1326.2004.00428.x. 21. Toplak H, Ziegler O, Keller U, Hamann A, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet. Early response to treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7:699-708. doi: 10.1111/j.1463- 1326.2005.00483.x. 22. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61. doi: 10.2337/ diacare.27.1.155. 23. Zheng J., Greenway F.L. Caenorhabditis elegans as a model for obesity research. Int J Obes (Lond). 2012;36(2):186-94. doi: 10.1038/ ijo.2011.93. 24. Neary M.T., Batterham R.L. Gut hormones: implications for the treatment of obesity. Pharmacol Ther. 2009;124(1):44-56. doi: 10.1016/j.pharmthera.2009.06.005. 25. Culbert K., Racine S., Klump K. Research Review: What we have learned about the causes of eating disorders - a synthesis of sociocultural, psychological, and biological research. J Child Psychol Psychiatry. 2015;56(11):114164. doi: 10.1111/jcpp.12441. 26. Peeters A.V., Beckers S., Verrijken A. Common variants in the gene for the serotonin receptor 6 (HTR6) do not contribute to obesity. J Genet. 2010;89(4):469-72. doi: 10.1007/s12041- 010-0066-2. 27. Власова И.И, Аметов А.С. Влияние терапии Сибутрамином (Меридиа) на композиционный состав тела, уровни пептида YY3-36 и серотонина у пациентов с экзо- генно-конституциональным ожирением. Терапевтический архив. 2010;82(8):44-7. 28. Caterson I.D., Finer N., Coutinho W., et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14(6): 523-30. Doi:10.1111/j.1463-1326.2011.01554.x. 29. Аметов А.С. Эффективное лечение ожирения-путь борьбы с эпидеми ей Diabetus mellipidus. Медицинский совет. 2013;2:78-83. 30. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Стратегия управления ожирением: итоги Всероссийской наблюдательной программы «ПримаВера». Ожирение и метаболизм. 2016;1:36-44. 31. Dedov I.I, et al. Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obes Facts. 2018;11:335-43. doi: 10.1159/000488880. 32. Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-37. doi: 10.1016/j.cmet.2013.04.008.
Автор для связи: Ирина Алексеевна Курникова, д.м.н., профессор, профессор кафедры госпитальной терапии с курсами эндокринологии, гематологии и клинической лабораторной диагностики медицинского института, Российский университет дружбы народов, куратор курса эндокринологии, Москва, Россия; cumikova@yandex.ru ORCID / eLibrary SPIN-код:
И.А. Курникова (I.A. Kurnikova), https://orcid.org/0000-0002-5712-9679; eLibrary SPIN-код: 8579-9455
Ш.Г. Гулова (Sh.G. Gulova), https://orcid.org/0000-0002-2411-5756
С.А. Бутурлина (S.A. Buturlina), https://orcid.org/0000-0002-8482-6787
И. Мохаммед (I. Mokhammed), https://orcid.org/0000-0003-3846-9106